For: | Guney-Coskun M, Basaranoglu M. Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy. World J Gastroenterol 2024; 30(43): 4682-4688 [PMID: 39575401 DOI: 10.3748/wjg.v30.i43.4682] |
---|---|
URL: | https://www.wjgnet.com/2150-5349/full/v30/i43/4682.htm |
Number | Citing Articles |
1 |
Jingyue Wang, Jing Qu, Mengliang Ye, Ru Feng, Xiang Hui, Xinyu Yang, Jingyu Jin, Qian Tong, Xianfeng Zhang, Yan Wang. Beyond conventional therapies: Gut microbiota modulation and macromolecular drugs in the battle against cardiometabolic diseases. Journal of Pharmaceutical Analysis 2025; : 101416 doi: 10.1016/j.jpha.2025.101416
|
2 |
Danyang Zhang, Haitao Shi, Chongcao Wei, Fenrong Chen, Pan Zhang, Xin Gao, Yan Wang. Analysis of causal effects on metabolic syndrome and inflammatory bowel disease: a Mendelian randomization study. Diabetology & Metabolic Syndrome 2025; 17(1) doi: 10.1186/s13098-025-01704-w
|
3 |
Shengnan Meng, Luonan Li, Shijie Yin, Yuxuan Zhao, Yaning Liu, Yuxi Zhang, Xiaolin Zhang, Fengxue Yu. The newly proposed dietary index for gut microbiota and its association with the risk of nonalcoholic fatty liver disease: the mediating role of body mass index. Diabetology & Metabolic Syndrome 2025; 17(1) doi: 10.1186/s13098-025-01801-w
|
4 |
Hao Zhang, Yuan Tian, Chunjie Xu, Miaomiao Chen, Zeyu Xiang, Lei Gu, Hanbing Xue, Qing Xu. Crosstalk between gut microbiotas and fatty acid metabolism in colorectal cancer. Cell Death Discovery 2025; 11(1) doi: 10.1038/s41420-025-02364-5
|